[Skip to Navigation]
January 1986

Imipramine and Chlordiazepoxide in Depressive and Anxiety Disorders: II. Efficacy in Anxious Outpatients

Author Affiliations

From the Clinical Psychopharmacology Laboratory, Department of Psychology, Boston University (Drs Kahn, McNair, and Fisher and Ms Frankenthaler); the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore (Drs Lipman and Covi); and the Department of Psychiatry, University of Pennsylvania, Philadelphia (Drs Rickels and Downing). Dr Fisher is now with the University of Texas Medical Branch, Galveston, and Dr Lipman is now with the Friends Hospital, Philadelphia.

Arch Gen Psychiatry. 1986;43(1):79-85. doi:10.1001/archpsyc.1986.01800010081010

• A double-blind, placebo-controlled comparison at three collaborating university sites included 242 patients diagnosed as having anxiety disorders. A two-week placebo washout period preceded random assignment to eight weeks of imipramine hydrochloride, chlordiazepoxide hydrochloride, or placebo treatment. Antianxiety effects of imipramine were superior to those of the other two agents by the second treatment week; these effects became more clearly significant thereafter and were independent of degree of both baseline depression and anxiety. Excluding patients with possible panic-phobic syndromes from the analyses removed most significant antiphobic and antidepressant effects of imipramine but left intact imipramine's significantly superior antianxiety effects.

Add or change institution